Executive summary

This MD Anderson study published in the Green Journal reported proton therapy for early stage NSCLC patients who were not suitable for SBRT due to lesion size and location. The study reported encouraging 5-year overall survival rate and recurrence-free rate.

The authors concluded that this long-term follow-up data demonstrated proton therapy with ablative doses is well tolerated and effective in medically inoperable early-stage NSCLC

Top cancer treatments